Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.
The latest report Serine Protein Kinase ATM – Pipeline Review, H1 2018, outlays comprehensive information on the Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) – Serine Protein Kinase ATM is a serine/threonine protein kinase. It activates checkpoint signaling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet a light (UVA), thereby acting as a DNA damage sensor. It plays a role in replication-dependent histone mRNA degradation. It binds DNA ends.
The molecules developed by companies in Phase I, Preclinical and Discovery stages are 3, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Ophthalmology which include indications Head And Neck Cancer, Adenocarcinoma, Colorectal Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Herpetic Keratitis, Human Papillomavirus (HPV) Associated Cancer, Lymphoma, Multiple Myeloma (Kahler Disease), Solid Tumor and Squamous Cell Carcinoma.
Furthermore, this report also reviews key players involved in Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
The report provides a snapshot of the global therapeutic landscape for Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1)
The report reviews Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
The report assesses Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics
To know more, click on the link below:
Related Reports:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
0124-4230204
